Curis Analyst Price Targets - Benzinga

Curis Inc

CRISNASDAQ

Trade with Public

Trade with Public

$0.8297

0.1725.52%

Últ. Act.: Nov 3, 12:00 PM

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Informe de acciones

Curis Analyst Price Targets

Wall Street analyst price targets and consensus rating for Curis (CRIS).

Price Target Range — 9 Quarters

Analyst Consensus — 3 Analysts

3Buy

Consensus RatingBuy# Analysts3Avg. Consensus PT$306Upside to Avg. PT+36750.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 17, 2026	HC Wainwright & Co.	Sara Nik	Maintained	Buy	$43
Jul 24, 2026	HC Wainwright & Co.	Sara Nik	PT Raise	Buy	$17→$43
Mar 20, 2026	HC Wainwright & Co.	Sara Nik	Maintained	Buy	$340
May 19, 2025	HC Wainwright & Co.	Joseph Pantginis	Assumes	Buy	$340
Mar 31, 2025	HC Wainwright & Co.	Edward White	PT Cut	Buy	$400→$320
Dec 10, 2024	HC Wainwright & Co.	Edward White	Maintained	Buy	$400
Nov 15, 2024	HC Wainwright & Co.	Edward White	Maintained	Buy	$400
Nov 1, 2024	HC Wainwright & Co.	Edward White	PT Cut	Buy	$520→$400
Sep 27, 2024	HC Wainwright & Co.	Edward White	Maintained	Buy	$520
Aug 1, 2024	HC Wainwright & Co.	Edward White	Maintained	Buy	$520
May 15, 2024	Truist Securities	Robyn Karnauskas	Maintained	Buy	$520
May 15, 2024	HC Wainwright & Co.	Edward White	Maintained	Buy	$520
May 15, 2024	Cantor Fitzgerald	Li Watsek	Maintained	Overweight	—
May 8, 2024	HC Wainwright & Co.	Edward White	Maintained	Buy	$520
Feb 9, 2024	HC Wainwright & Co.	Edward White	PT Cut	Buy	$1020→$520
Nov 17, 2023	Truist Securities	Robyn Karnauskas	Initiate	Buy	$520

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Curis, Maintains $43 Price Target

HC Wainwright & Co. analyst Sara Nik reiterates Curis (NASDAQ:CRIS) with a Buy and maintains $43 price target.

Benzinga Newsdesk

Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus

Curis gained attention after positive emavusertib data as analyst raised its price target to $43 and highlighted upcoming trial catalysts.

Vandana Singh

PRO
HC Wainwright & Co. Maintains Buy on Curis, Raises Price Target to $43

HC Wainwright & Co. analyst Sara Nik maintains Curis (NASDAQ:CRIS) with a Buy and raises the price target from $17 to $43.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Curis, Maintains $17 Price Target

HC Wainwright & Co. analyst Sara Nik reiterates Curis (NASDAQ:CRIS) with a Buy and maintains $17 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Assumes Curis at Buy, Announces Price Target of $17

HC Wainwright & Co. analyst Joseph Pantginis assumes Curis (NASDAQ:CRIS) with a Buy rating and announces Price Target of $17.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Curis, Lowers Price Target to $16

HC Wainwright & Co. analyst Edward White maintains Curis (NASDAQ:CRIS) with a Buy and lowers the price target from $20 to $16.

Benzinga Newsdesk